Strides Pharma Science Limited (STAR.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹1,093.30 (+5.83%) as of
Key statistics
- Market cap
- 100.77B
- P/E (TTM)
- 16.43
- Forward P/E
- 11.46
- EPS (TTM)
- 66.55
- Dividend yield
- 0.48%
- 52-week range
- 768.65 – 1,260.90
- Beta
- 0.37
- Revenue (TTM)
- 50.04B
- Profit margin
- 12.26%
- Analyst target
- ₹1,338.67
- Volume
- 787.20k
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Bengaluru, India
- Employees
- 3,535
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.